SeqOne

\SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company, founded in 2017, has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Notably, its last investment round amounted to €20.00M, which was led by Omnes Capital, Elaia, Mérieux Equity Partners, and Supernova Invest on 22 May 2025. SeqOne is situated in France and operates within the Analytics, Big Data, Biotechnology, and Health Care industries, with a clear focus on advancing personalized medicine through innovative genomic analysis solutions.